ChenSZhuBLuoZWangYHuQZhouL. The Fibrosis-5 index predicts major adverse cardiovascular events in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Angiology. 2025;76:604–5.
2.
SterlingRKLissenEClumeckN, et al.Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-1325.
3.
SongJLiuYChenJ, et al.Fibrosis-4 stage of liver fibrosis predicts cardiovascular outcomes in acute coronary syndrome patients with and without type 2 diabetes mellitus. Diabetes Res Clin Pract. 2023;195:110206.
4.
NakashimaMMiyoshiTTanakayaM, et al.Prognostic value of the liver fibrosis marker fibrosis-5 index in patients with severe isolated tricuspid regurgitation: comparison with fibrosis-4 index. Heart Ves. 2023;38:1181-1189.
5.
WallentinLBeckerRCBudajA, et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
6.
WiviottSDBraunwaldEMcCabeCH, et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015.
7.
ByrneRARosselloXCoughlanJ, et al.2023 ESC guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European society of cardiology (ESC). Eur Heart J. 2023;44:3720-3826.
